Home / Economy / News / After the anti-diabetic market, India's cardiac market in for a shake-up

After the anti-diabetic market, India's cardiac market in for a shake-up

Sun Pharma has the largest share in the Indian cardiac market, followed by Torrent Pharma, Lupin and USV

Premium

3 min read Last Updated : Dec 04 2022 | 10:21 AM IST

After the anti-diabetic market, India's cardiology market is now set for a churn as Swiss drugmaker Novartis’ blockbuster drug for heart failure patients Vymada or Entresto is set to go off patent in January.

Trade sources say that this is one of the fastest growing drugs in the Rs 23,000 crore cardiac market in the country.

Entresto or Vymada as it is sold in India is a combination of Sacubitril and Valsartan.

According to data from market research firm AWACS, the cardiac market in India is dominated by antihypertensives which contribute nearly 53 per cent of the market, followed by

What you get on BS Premium?

Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
Pick your 5 favourite companies, get a daily email with all news updates on them.
Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
Preferential invites to Business Standard events.
Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.

VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in